Last updated on October 2018

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis


Brief description of study

The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.

Clinical Study Identifier: NCT03129100

Contact Investigators or Research Sites near you

Start Over

Federico Javier Ariel

Clinica Adventista de Belgrano
Ciudad de Buenos Aires, Argentina
  Connect »

Jose Maldonado Cocco

Consultorios Reumatologicos Pampa
Ciudad Autonoma de Buenos Aire, Argentina
  Connect »